Featured Research

from universities, journals, and other organizations

Type of cell therapy does not improve walking ability for patients with peripheral artery disease

Date:
November 18, 2013
Source:
The JAMA Network Journals
Summary:
Researchers studied whether therapy with granulocyte-macrophage colony stimulating factor, an agent that functions as a white blood cell growth factor, would improve walking performance in patients with symptomatic peripheral artery disease (a form of vascular disease in which there is partial or total blockage of an artery, usually one leading to a leg or arm).

Joseph Poole, M.D., Ph.D., of the Emory University School of Medicine, Atlanta, and colleagues studied whether therapy with granulocyte-macrophage colony stimulating factor (GM-CSF), an agent that functions as a white blood cell growth factor, would improve walking performance in patients with symptomatic peripheral artery disease (a form of vascular disease in which there is partial or total blockage of an artery, usually one leading to a leg or arm).

"Peripheral artery disease (PAD) affects more than 8 million individuals in the United States. Although exercise, smoking cessation, antiplatelet therapy, cilostazol [a medication for PAD], statins, and revascularization are used to treat PAD, men and women with PAD have significantly greater functional impairment and faster functional decline than those without PAD. Stem and progenitor cell (PC) therapy that promotes neoangiogenesis [formation of blood vessels] is an emerging treatment modality in PAD," according to background information in the article. Progenitor cells are involved in vascular repair and regeneration.

The phase 2, placebo-controlled study included 159 patients with intermittent claudication (pain in leg muscles, aggravated by walking and caused by an insufficient supply of blood). Participants were randomized to received 4 weeks of subcutaneous (under the skin) injections of GM-CSF (leukine), 3 times a week (n = 80), or placebo (n = 79).

The researchers found that therapy with GM-CSF did not improve treadmill walking time, a measure of PAD severity at 3-month follow-up. "The improvement in a subset of secondary outcomes observed with GM-CSF suggests that GM-CSF may warrant further study in patients with claudication. In addition, further investigation is needed to investigate the variability of responsiveness to GM-CSF and its clinical significance."


Story Source:

The above story is based on materials provided by The JAMA Network Journals. Note: Materials may be edited for content and length.


Journal Reference:

  1. Joseph Poole, Kreton Mavromatis, José N. Binongo, Ali Khan, Qunna Li, Mohamed Khayata, Elizabeth Rocco, Matthew Topel, Xin Zhang, Charlene Brown, Matthew A. Corriere, Jonathan Murrow, Salman Sher, Stephanie Clement, Khuram Ashraf, Amr Rashed, Tarek Kabbany, Robert Neuman, Alanna Morris, Arshad Ali, Salim Hayek, John Oshinski, Young-sup Yoon, Edmund K. Waller, Arshed A. Quyyumi. Effect of Progenitor Cell Mobilization With Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Peripheral Artery Disease. JAMA, 2013; DOI: 10.1001/jama.2013.282540

Cite This Page:

The JAMA Network Journals. "Type of cell therapy does not improve walking ability for patients with peripheral artery disease." ScienceDaily. ScienceDaily, 18 November 2013. <www.sciencedaily.com/releases/2013/11/131118102624.htm>.
The JAMA Network Journals. (2013, November 18). Type of cell therapy does not improve walking ability for patients with peripheral artery disease. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2013/11/131118102624.htm
The JAMA Network Journals. "Type of cell therapy does not improve walking ability for patients with peripheral artery disease." ScienceDaily. www.sciencedaily.com/releases/2013/11/131118102624.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) — Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) — Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) — At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Xtreme Eating: Your Daily Caloric Intake All On One Plate

Xtreme Eating: Your Daily Caloric Intake All On One Plate

Newsy (July 30, 2014) — The Center for Science in the Public Interest released its 2014 list of single meals with whopping calorie counts. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

    Technology News



      Save/Print:
      Share:  

      Free Subscriptions


      Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

      Get Social & Mobile


      Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

      Have Feedback?


      Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
      Mobile iPhone Android Web
      Follow Facebook Twitter Google+
      Subscribe RSS Feeds Email Newsletters
      Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins